105 related articles for article (PubMed ID: 38943140)
1. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.
Cinti F; Leccisotti L; Sorice GP; Capece U; D'Amario D; Lorusso M; Gugliandolo S; Morciano C; Guarneri A; Guzzardi MA; Mezza T; Capotosti A; Indovina L; Ferraro PM; Iozzo P; Crea F; Giordano A; Giaccari A
Cardiovasc Diabetol; 2023 Dec; 22(1):349. PubMed ID: 38115004
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
Correale M; Antohi EL; Inciardi RM; Mazzeo P; Coiro S; Ishihara S; Petroni R; Monitillo F; Leone M; Triggiani M; Sarwar CMS; Dungen HD; Talha KM; Brunetti ND; Butler J; Nodari S;
ESC Heart Fail; 2023 Jun; 10(3):2066-2073. PubMed ID: 36924023
[TBL] [Abstract][Full Text] [Related]
4. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
5. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
Packer M
J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
[TBL] [Abstract][Full Text] [Related]
6. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
7. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Sato T; Aizawa Y; Yuasa S; Kishi S; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Sato M; Okabe M
Cardiovasc Diabetol; 2018 Jan; 17(1):6. PubMed ID: 29301516
[TBL] [Abstract][Full Text] [Related]
8. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
9. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus.
Song XT; Wei YL; Rui YF; Fan L
J Diabetes Complications; 2023 Jul; 37(7):108509. PubMed ID: 37235925
[TBL] [Abstract][Full Text] [Related]
11. The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Bendotti G; Montefusco L; Pastore I; Lazzaroni E; Lunati ME; Fiorina P
J Endocrinol Invest; 2023 Dec; 46(12):2445-2452. PubMed ID: 37535237
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
15. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review.
Panico C; Bonora B; Camera A; Chilelli NC; Prato GD; Favacchio G; Grancini V; Resi V; Rondinelli M; Zarra E; Pintaudi B
Cardiovasc Diabetol; 2023 Jun; 22(1):164. PubMed ID: 37391739
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
18. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
Lee SE; Nam H; Choi HS; Kim H; Kyoung DS; Kim KA
Diabetes Metab J; 2022 Jul; 46(4):567-577. PubMed ID: 35130688
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]